Anthrax vaccine antigen-adjuvant formulations completely protect New Zealand white rabbits against challenge with Bacillus anthracis Ames strain spores.
about
Phage display--a powerful technique for immunotherapy: 2. Vaccine deliveryParticulate delivery systems for vaccination against bioterrorism agents and emerging infectious pathogensMutated and bacteriophage T4 nanoparticle arrayed F1-V immunogens from Yersinia pestis as next generation plague vaccinesChemically modified peptides based on the membrane-proximal external region of the HIV-1 envelope induce high-titer, epitope-specific nonneutralizing antibodies in rabbitsDesigning a soluble near full-length HIV-1 gp41 trimer.In vitro and in vivo activities of recombinant anthrax protective antigen co-expressed with thioredoxin in Escherichia coli.Biophysical characterization and immunization studies of dominant negative inhibitor (DNI), a candidate anthrax toxin subunit vaccine.Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine ResearchGeneration of affinity-tagged fluoromycobacteriophages by mixed assembly of phage capsids.Adjuvants for human vaccines.Anthrax vaccines: present status and future prospects.Glycan surface antigens from Bacillus anthracis as vaccine targets: current status and future perspectives.Bacteriophage T4 as a Nanoparticle Platform to Display and Deliver Pathogen Antigens: Construction of an Effective Anthrax Vaccine.Using Telemetry Data to Refine Endpoints for New Zealand White Rabbits Challenged with Bacillus anthracis.
P2860
Q26865013-8FF6275F-4E22-4BE3-B549-4FCEAA382844Q27011190-145102B3-9118-49CD-80C1-470E192853FDQ28678943-C2F848AE-B3C8-443C-ADD8-05CF72585435Q34057672-F428EE24-08A4-46B1-AC72-6A51711C9F9AQ34489464-1C1528A0-FCBB-4DD2-87E1-17FC2CEA0D79Q34861411-61E3F381-63B1-4979-99AF-9B927BAD5E5AQ34909572-90887BE2-D124-44EB-9D9E-FD407F28640EQ35861256-7764BB4A-D219-462B-BD6B-43D2F8A1AFC4Q37123622-2C92CB0C-A80B-4CFB-ADC6-C54600AF9769Q38004229-0CF5F432-EC44-4E94-B2F2-DC34533A1AE4Q38132268-CCBC668E-079D-4ABE-A851-61A81B2F9CEEQ38215454-AEE9609E-C1DE-46FC-995B-4FA011F48DB6Q40259573-6CC24A41-677C-476D-AA01-1C0623976153Q47284551-D58789C3-853C-4673-9885-3994E0431BD2
P2860
Anthrax vaccine antigen-adjuvant formulations completely protect New Zealand white rabbits against challenge with Bacillus anthracis Ames strain spores.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Anthrax vaccine antigen-adjuva ...... anthracis Ames strain spores.
@ast
Anthrax vaccine antigen-adjuva ...... anthracis Ames strain spores.
@en
type
label
Anthrax vaccine antigen-adjuva ...... anthracis Ames strain spores.
@ast
Anthrax vaccine antigen-adjuva ...... anthracis Ames strain spores.
@en
prefLabel
Anthrax vaccine antigen-adjuva ...... anthracis Ames strain spores.
@ast
Anthrax vaccine antigen-adjuva ...... anthracis Ames strain spores.
@en
P2093
P2860
P356
P1476
Anthrax vaccine antigen-adjuva ...... anthracis Ames strain spores.
@en
P2093
Carl R Alving
Gary R Matyas
Julie Lovchik
Kristina K Peachman
Mangala Rao
Rick C Lyons
Sathish B Shivachandra
Venigalla B Rao
P2860
P356
10.1128/CVI.05376-11
P577
2011-11-16T00:00:00Z